Short answer: HRT primarily treats menopause-related hormone and tissue symptoms; sexual wellness care evaluates distressing desire and function after a broader look at causes. They overlap when dryness or pain drives low interest — but they are not the same clinical pathway.
"Women's health" gets treated as one catch-all category, but HRT and sexual wellness care are related, not identical — they answer genuinely different clinical questions. Understanding the distinction actually helps you get to the right treatment faster.
Two Different Starting Questions
Menopausal hormone therapy primarily treats symptoms caused by the menopausal transition or low estrogen — hot flashes, night sweats, genitourinary symptoms, and bone loss especially. Sexual wellness care evaluates and treats distressing low desire and other sexual-function concerns, which can have hormonal, physical, psychological, medication-related, or relationship-related causes.[5] HRT generally means estrogen with or without a progestogen — systemic estrogen is the most effective treatment for hot flashes and night sweats and helps prevent bone loss; low-dose vaginal estrogen targets genitourinary symptoms specifically.[1]If you have a uterus, systemic estrogen usually needs adequate progestogen protection to reduce endometrial cancer risk — that's a menopause-treatment decision based on uterus status and estrogen exposure, not something designed to diagnose or treat low libido.[1]
Sexual wellness care starts from a different clinical question entirely: is low desire persistent and distressing, is it generalized or situational, and is it better explained by pain, vaginal dryness, medications, mood, sleep, chronic illness, relationship context, or something else?[2]HSDD specifically is a defined diagnosis — persistent or recurrent low desire causing real personal distress or interpersonal difficulty. It's not the same thing as occasionally having less interest in sex, having a different desire level than your partner, or feeling low desire during a rough patch.[2] "Acquired, generalized" HSDD specifically means desire dropped after a period without the problem and shows up across partners, activities, and settings — that distinction matters because FDA-approved bremelanotide is only approved for that exact presentation, in premenopausal women.[4]
Where They Genuinely Overlap
HRT and sexual wellness can overlap because menopause really does affect sexual comfort and desire. Declining estrogen can cause vaginal dryness, thinning vaginal tissue, less lubrication, and pain with penetration — and understandably, pain or anticipated pain reduces interest in sex.[6] In that situation, treating the menopausal symptoms can improve sexual function indirectly: systemic estrogen may help hot flashes, sleep, and vaginal symptoms, while local vaginal estrogen specifically helps dryness and pain — removing those barriers can make sex more comfortable without ever touching desire directly.[6]
Worth being honest about scale here: the evidence doesn't support treating HRT as a universal "libido treatment." A systematic review and meta-analysis found menopausal hormone therapy may produce a small improvement in overall sexual functioning, likely partly by reducing genitourinary symptoms — but it doesn't resolve every form of low desire.[7]
A practical way to think about where to start: if low libido seems mostly linked to hot flashes, sleep loss, vaginal dryness, or pain with sex, menopause-focused care is often the more logical first step — HRT, local vaginal therapy, or other genitourinary-syndrome treatments may matter more here than a medication aimed specifically at desire.[5] If low desire persists despite comfortable sex and adequately treated menopause symptoms — or shows up entirely outside a menopause context — an HSDD or broader sexual-wellness evaluation becomes the more appropriate path, looking at emotional wellbeing, relationship context, medications, sexual pain, medical conditions, and your own level of distress.[2]
Different Mechanisms, Different Eligibility
FDA-approved bremelanotide (Vyleesi) is an on-demand subcutaneous medication specifically for premenopausal women with acquired, generalized HSDD — not approved for postmenopausal women, men, situational low desire, or desire issues better explained by another medical condition, psychiatric condition, relationship issue, medication, or substance use.[4] Bremelanotide and HRT genuinely work differently and have separate suitability criteria: bremelanotide is a melanocortin receptor agonist for a narrowly defined desire disorder, while estrogen therapy treats menopausal symptoms and should be chosen based on menopause status, symptom pattern, uterus status, and personal risk factors.[4]
Sometimes You Need Both — or Neither
It's genuinely possible to need both kinds of care at once. A menopausal patient might use evidence-based treatment for vaginal dryness and painful sex while also getting a separate evaluation for persistent, distressing generalized low desire. Ideally these get coordinated, since symptoms, contraindications, and treatment goals can overlap.[3]It's just as possible to need neither — if the real driver is something like an SSRI side effect, depression, relationship conflict, chronic stress, sleep problems, thyroid disease, or pelvic pain, that's exactly why an individualized assessment matters more than routing every sexual concern into one generic "women's health" pathway.[3]
The Regulatory Picture Differs Too
FDA-approved estradiol and micronized progesterone products exist for menopause care; FDA-approved Vyleesi has a narrow HSDD indication; compounded hormones, compounded bremelanotide, and compounded oxytocin are all non-FDA-approved finished drug products, regardless of which category they're used in.[8]Terms like "compounded," "bioidentical," "natural," or "customized" shouldn't be used to blur these categories together. A compounded preparation can have a legitimate, patient-specific role in limited circumstances, but it doesn't get the same product-specific FDA review for safety, effectiveness, manufacturing quality, or labeling that an FDA-approved product does.[8]
The Bottom Line
HRT treats menopause-related hormone and tissue symptoms. Sexual wellness treatment addresses distressing desire and function concerns after a broader look at what's actually driving them. They can overlap, complement each other, or turn out to be entirely separate issues — which is exactly why the right starting point is your actual symptom pattern and its likely causes, not a one-size-fits-all label.
Worth comparing providers on both fronts — how they handle menopause-symptom treatment and how they evaluate sexual wellness concerns — since the right fit may involve either, both, or a referral to something else entirely.
Sources
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society — The Menopause Society / Menopause menopause.org
- International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women — Mayo Clinic Proceedings mayoclinicproceedings.org
- Treatment of Hypoactive Sexual Desire Disorder Among Women — Focus (via PMC, National Institutes of Health) pmc.ncbi.nlm.nih.gov
- Vyleesi (Bremelanotide) Prescribing Information — U.S. Food and Drug Administration accessdata.fda.gov
- Sexual Health — The Menopause Society menopause.org
- Sex and Menopause: Treatment for Symptoms — National Institute on Aging, National Institutes of Health nia.nih.gov
- Hormone Therapy for Sexual Function in Perimenopausal and Postmenopausal Women: A Systematic Review and Meta-Analysis — Menopause (via PMC, National Institutes of Health) pmc.ncbi.nlm.nih.gov
- Compounding and the FDA: Questions and Answers — U.S. Food and Drug Administration fda.gov
Frequently Asked Questions
Will HRT fix my low libido?
Not reliably on its own. Research shows HRT may produce a small improvement in overall sexual function, largely by reducing genitourinary symptoms — but it doesn't resolve every form of low desire.[7]
Should I start with HRT or a sexual wellness evaluation?
If your symptoms are mainly hot flashes, sleep disruption, or vaginal dryness/pain, menopause-focused care is often the logical first step. If low desire persists despite that, or exists outside a menopause context, a dedicated HSDD evaluation makes more sense.[5]
Can I need both HRT and sexual wellness treatment?
Yes — it's common to need evidence-based treatment for menopause symptoms like vaginal dryness alongside a separate evaluation for persistent low desire, and ideally these are coordinated together.[3]
Is bremelanotide the same kind of treatment as estrogen therapy?
No — they work through entirely different mechanisms and have separate eligibility criteria. Bremelanotide targets a specific desire disorder; estrogen therapy treats menopausal symptoms.[4]